Cytokine release syndrome
    
     
11
    
1
 
Infections and infestations

     Other pathogen infections
     Bacterial infections
     Fungal infections
     Viral infections
     Pneumonia
     Sepsis
    
44
19
15
13
9
7
    
25
12
7
4
8
6
 
Investigations
     Increased alanine aminotransferase
     Increased aspartate aminotransferase
     Increased weight
    

12
11
11
    

6
4
0
 
Metabolism and nutrition disorders

     Hypokalemia
     Hypomagnesemia
     Hyperglycemia
     Decreased appetite
     Hypophosphatemia
    
    
 
23
12
11
10
6
 
6
0
7
3
5
 
Musculoskeletal and connective tissue disorders
     Back pain
     Pain in extremity
     Bone pain
     Arthralgia
14
12
11
10
    
2
1
3
2
 
Nervous system disorders

     Headache
     Tremor‡
     Dizziness
    
    
36
20
14
   
3
1
< 1
 
Psychiatric disorders

     Insomnia
    
    
15
    
0
 
Respiratory, thoracic, and mediastinal disorders

     Cough
     Dyspnea§
      ​
   
19
15
    
0
5
 
Skin and subcutaneous tissue disorders

     Rash¶
    
21
   
2
 
Vascular disorders

     Hypotension
     Hypertension
11
8
2
5
Additional important adverse reactions that did not meet the threshold criteria for inclusion in Table 2 were:
Blood and lymphatic system disorders: leukocytosis (2%), lymphopenia (1%)
Cardiac disorders: tachycardia (8%)
General disorders and administration site conditions: edema (5%)
Immune system disorders: cytokine storm (1%)
Invetigations: decreased immunoglobulins (9%), increased blood bilirubin (8%), increased gamma-glutamyl-transferase (6%), increased liver enzymes (1%)
Metabolism and nutrition disorders: tumor lysis syndrome (4%), hypoalbuminemia (4%)
Nervous system disorders: encephalopathy (5%), paresthesia (5%), aphasia (4%), convulsion (2%), memory impairmen